Capitolo 30 · Pharmaceutical products
3001.90.00
Other
- 3001 Glands and other organs for organo-therapeutic uses, dried, whether or not powdered; extracts of glands or other organs or of their secretions for organo-therapeutic uses; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, not elsewhere specified or included
- - Other
Các tuyến và các bộ phận cơ thể khác dùng để chữa bệnh, ở dạng khô, đã hoặc chưa làm thành dạng bột; chiết xuất từ các tuyến hoặc các bộ phận cơ thể khác hoặc từ các dịch tiết của chúng dùng để chữa bệnh; heparin và các muối của nó; các chất khác từ người hoặc động vật được điều chế dùng cho phòng bệnh hoặc chữa bệnh, chưa được chi tiết hoặc ghi ở nơi khác / - Loại khác
Imposte applicabili nel 2026
Fonte: tariffa consolidata BT2026 (aggiornata al 05/04/2026)Aliquote preferenziali speciali (ALS) – 2026
| FTA | Aliquota | Base dei dati | Prova dell'origine | Base giuridica | Stato |
|---|---|---|---|---|---|
| AANZFTA | 0% Più bassa pubblicata | Tariffa consolidata BT2026 2022 - 2027 (một mức cho cả giai đoạn) |
AANZ | 121/2022/NĐ-CP | Ad valorem |
| ACFTA | 0% Più bassa pubblicata | Tariffa consolidata BT2026 2022 - 2027 (một mức cho cả giai đoạn) |
E | 118/2022/NĐ-CP | Ad valorem |
| AHKFTA | 0% Più bassa pubblicata | Tariffa consolidata BT2026 2026 |
AHK | 123/2022/NĐ-CP | Ad valorem |
| AIFTA | 0% Più bassa pubblicata | Tariffa consolidata BT2026 01/01/2026 - 31/12/2026 |
AI | 122/2022/NĐ-CP | Ad valorem |
| AJCEP | 0% Più bassa pubblicata | Tariffa consolidata BT2026 01/4/2026 - 31/3/2027 |
AJ | 120/2022/NĐ-CP | Ad valorem |
| AKFTA | 0% Più bassa pubblicata | Tariffa consolidata BT2026 2022 - 2027 (một mức cho cả giai đoạn) |
AK | 119/2022/NĐ-CP | Ad valorem |
| ATIGA | 0% Più bassa pubblicata | Tariffa consolidata BT2026 2026 |
D | 126/2022/NĐ-CP | Ad valorem |
| CPTPP | 0% Più bassa pubblicata | Tariffa consolidata BT2026 (VI) |
CPTPP | 115/2022/NĐ-CP | Ad valorem |
| EVFTA | 0% Più bassa pubblicata | Tariffa consolidata BT2026 2026 |
EUR.1 | 116/2022/NĐ-CP | Ad valorem |
| RCEP (Allegato A) BN, KH, ID, LA, MY, MM, PH, SG, TH |
0% Più bassa pubblicata | Tariffa consolidata BT2026 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| RCEP (Allegato B) AU |
0% Più bassa pubblicata | Tariffa consolidata BT2026 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| RCEP (Allegato C) CN |
0% Più bassa pubblicata | Tariffa consolidata BT2026 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| RCEP (Allegato D) JP |
0% Più bassa pubblicata | Tariffa consolidata BT2026 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| RCEP (Allegato E) KR |
0% Più bassa pubblicata | Tariffa consolidata BT2026 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| RCEP (Allegato F) NZ |
0% Più bassa pubblicata | Tariffa consolidata BT2026 2026 |
RCEP Form / Declaration of origin | 129/2022/NĐ-CP | Ad valorem |
| UKVFTA | 0% Più bassa pubblicata | Tariffa consolidata BT2026 2026 |
EUR.1 | 117/2022/NĐ-CP | Ad valorem |
| VCFTA | 0% Più bassa pubblicata | Tariffa consolidata BT2026 2026 |
VC | 112/2022/NĐ-CP | Ad valorem |
| VJEPA | 0% Più bassa pubblicata | Tariffa consolidata BT2026 01/4/2026 - 31/3/2027 |
JV · Form VJ | 124/2022/NĐ-CP | Ad valorem |
| VKFTA | 0% Più bassa pubblicata | Tariffa consolidata BT2026 2026 |
VK | 125/2022/NĐ-CP | Ad valorem |
| VN-EAEU | 0% Più bassa pubblicata | Tariffa consolidata BT2026 2026 |
EAV | 113/2022/NĐ-CP | Ad valorem |
| VN-LAO | 0% Più bassa pubblicata | Tariffa consolidata BT2026 | S | 206/2025/NĐ-CP | Ad valorem |
| VNCU | 0% Più bassa pubblicata | Tariffa consolidata BT2026 2023 - 2027 |
VNCB · Form VC (Cuba) | 114/2022/NĐ-CP | Ad valorem |
| VIFTA | 0% Più bassa pubblicata | Tariffa consolidata BT2026 2026 |
Form VI (verify) | 131/2024/NĐ-CP | Ad valorem |
| VN-CAM | Nessun dato | Nessun dato | S | 56/2026/NĐ-CP | Nessun dato |
Un'aliquota pubblicata non significa che le merci siano ammissibili. Sono necessari il rispetto delle regole di origine e una prova dell'origine valida.
Esegui lo Smart Tariff Advisory Confronta gli ALS Calcola le imposte
Storico delle aliquote / riduzione per anno
Dai fogli delle liste ALS 2022–2027
| FTA | Periodi |
|---|---|
| ACFTA AC · riga 4451 |
2022 - 2027 (một mức cho cả giai đoạn)0%
|
| ATIGA AT · riga 4412 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| AJCEP AJ · riga 4450 |
30/12/2022 - 31/3/20230%
01/4/2023 - 31/3/20240%
01/4/2024 - 31/3/20250%
01/4/2025 - 31/3/20260%
01/4/2026 - 31/3/20270%
01/4/2027 - 31/3/20280%
|
| VJEPA VJ · riga 4454 |
30/12/2022 - 31/3/20230%
01/4/2023 - 31/3/20240%
01/4/2024 - 31/3/20250%
01/4/2025 - 31/3/20260%
01/4/2026 - 31/3/20270%
01/4/2027 - 31/3/20280%
|
| AKFTA AK · riga 4454 |
2022 - 2027 (một mức cho cả giai đoạn)0%
Aliquota con esclusioni: 0 |
| AANZFTA AANZ · riga 4418 |
2022 - 2027 (một mức cho cả giai đoạn)0%
Colonna aliquota F (nascosta): 0 |
| AIFTA AI · riga 4414 |
30/12/20220%
31/12/2022 - 30/12/20230%
31/12/2023 - 30/12/20240%
31/12/2024 - 31/12/20250%
01/01/2026 - 31/12/20260%
01/01/2027 - 31/12/20270%
|
| VKFTA VK · riga 4414 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| VCFTA VC · riga 4461 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| VN-EAEU EAV · riga 4458 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| VNCU VNCU · riga 586 |
20220%
2023 - 20270%
|
| AHKFTA AKH · riga 4466 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| EVFTA EV-NK · riga 4437 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| UKVFTA UKV · riga 4439 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| CPTPP CPTPP · riga 4437 |
(I) → 2021*0%
(II) → 2022*0%
(III) → 2023*0%
(IV) → 2024*0%
(V) → 2025*0%
(VI) → 2026*0%
(VII) → 2027*0%
|
| RCEP A RCEPT-A · riga 4458 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| RCEP B B · riga 4458 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| RCEP C C · riga 4458 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| RCEP D D · riga 4458 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| RCEP E E · riga 4461 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| RCEP F F · riga 4458 |
20220%
20230%
20240%
20250%
20260%
20270%
|
| VIFTA VI · riga 4103 |
20240%
20250%
20260%
20270%
Colonna ausiliaria J: 8 |
* I periodi CPTPP (I)–(VII) sono associati agli anni tramite confronto con il BT2026 (dati DERIVATI – da verificare).
Consulenza e avvisi
Valutazione generale (origine non considerata). Esegui lo Smart Tariff Advisory per una valutazione specifica per origine.
YELLOW – REVIEW REQUIRED DOC-004 Other item policy
- Descrizione
- Item policy (source, Vietnamese): NL làm thuốc XK, NK là dược chất và BTP thuốc (09/2024/TT-BYT-DM7)
- Riferimento normativo
- 09/2024/TT-BYT-DM
- Azione consigliata
- Read the referenced instruments.
- Stato della verifica
- Atto citato nella fonte; validità non verificata
YELLOW – REVIEW REQUIRED TAX-001 Several VAT rates
- Descrizione
- The VAT column shows "5/8/10".
- Riferimento normativo
- 181/2025/NĐ-CP
- Azione consigliata
- Determine the VAT rate by the nature of goods and reduction rules (174/2025/NĐ-CP, Annex I/II).
- Stato della verifica
- Non verificato – controllo necessario
GRAY – DATA UNAVAILABLE TR-004 Not Assessed – Additional Regulatory Verification Required
- Descrizione
- The source file records no trade remedy for 3001.90.00. This does NOT mean there is no risk.
- Azione consigliata
- Check the MOIT Trade Remedies Authority database.
- Stato della verifica
- Non verificato – controllo necessario
GREEN – VERIFIED DQ-001 MFN rate present in the source
- Descrizione
- The MFN rate 0% for 3001.90.00 was checked against BT2026 (cell BT2026!N4532), basis 26/2023/NĐ-CP.
- Riferimento normativo
- 26/2023/NĐ-CP
- Azione consigliata
- Verification scope: matched against source file version 2026.04.05; not a substitute for the legal text.
- Stato della verifica
- Verificato rispetto al file tariffario di origine
Note di capitolo
Notes
1. This Chapter does not cover:
(a) Foods or beverages (such as dietetic, diabetic or fortified foods, food supplements, tonic beverages and mineral waters), other than nutritional preparations for intravenous administration (Section IV);
(b) Products, such as tablets, chewing gum or patches (transdermal systems), containing nicotine and intended to assist tobacco use cessation (heading 24.04);
(c) Plasters specially calcined or finely ground for use in dentistry (heading 25.20);
(d) Aqueous distillates or aqueous solutions of essential oils, suitable for medicinal uses (heading 33.01);
(e) Preparations of headings 33.03 to 33.07, even if they have therapeutic or prophylactic properties;
(f) Soap or other products of heading 34.01 containing added medicaments;
(g) Preparations with a basis of plaster for use in dentistry (heading 34.07);
(h) Blood albumin not prepared for therapeutic or prophylactic uses (heading 35.02); or
(ij) Diagnostic reagents of heading 38.22.
2. For the purposes of heading 30.02, the expression “immunological products” applies to peptides and proteins (other than goods of heading 29.37) which are directly involved in the regulation of immunological processes, such as monoclonal antibodies (MAB), antibody fragments, antibody conjugates and antibody fragment conjugates, interleukins, interferons (IFN), chemokines and certain tumor necrosis factors (TNF), growth factors (GF), hematopoietins and colony stimulating factors (CSF).
3. For the purposes of headings 30.03 and 30.04 and of Note 4 (d) to this Chapter, the following are to be treated:
(a) As unmixed products:
(1) Unmixed products dissolved in water;
(2) All goods of Chapter 28 or 29; and
(3) Simple vegetable extracts of heading 13.02, merely standardised or dissolved in any solvent;
(b) As products which have been mixed:
(1) Colloidal solutions and suspensions (other than colloidal sulphur);
(2) Vegetable extracts obtained by the treatment of mixtures of vegetable materials; and
(3) Salts and concentrates obtained by evaporating natural mineral waters.
4. Heading 30.06 applies only to the following, which are to be classified in that heading and in no other heading of the Nomenclature:
(a) Sterile surgical catgut, similar sterile suture materials (including sterile absorbable surgical or dental yarns) and sterile tissue adhesives for surgical wound closure;
(b) Sterile laminaria and sterile laminaria tents;
(c) Sterile absorbable surgical or dental haemostatics; sterile surgical or dental adhesion barriers, whether or not absorbable;
(d) Opacifying preparations for X-ray examinations and diagnostic reagents designed to be administered to the patient, being unmixed products put up in measured doses or products consisting of two or more ingredients which have been mixed together for such uses;
(e) Placebos and blinded (or double-blinded) clinical trial kits for use in recognised clinical trials, put up in measured doses, even if they might contain active medicaments;
(f) Dental cements and other dental fillings; bone reconstruction cements;
(g) First-aid boxes and kits;
(h) Chemical contraceptive preparations based on hormones, on other products of heading 29.37 or on spermicides;
(ij) Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments;
(k) Waste pharmaceuticals, that is, pharmaceutical products which are unfit for their original intended purpose due to, for example, expiry of shelf life; and
(l) Appliances identifiable for ostomy use, that is, colostomy, ileostomy and urostomy pouches cut to shape and their adhesive wafers or faceplates.
Subheading Notes
1. For the purposes of subheadings 3002.13 and 3002.14, the following are to be treated:
(a) As unmixed products, pure products, whether or not containing impurities;
(b) As products which have been mixed:
(1) The products mentioned in (a) above dissolved in water or in other solvents;
(2) The products mentioned in (a) and (b) (1) above with an added stabiliser necessary for their preservation or transport; and
(3) The products mentioned in (a), (b) (1) and (b) (2) above with any other additive.
2. Subheadings 3003.60 and 3004.60 cover medicaments containing artemisinin (INN) for oral ingestion combined with other pharmaceutical active ingredients, or containing any of the following active principles, whether or not combined with other pharmaceutical active ingredients: amodiaquine (INN); artelinic acid or its salts; artenimol (INN); artemotil (INN); artemether (INN); artesunate (INN); chloroquine (INN); dihydroartemisinin (INN); lumefantrine (INN); mefloquine (INN); piperaquine (INN); pyrimethamine (INN) or sulfadoxine (INN).
(*): Dạng uống là dạng sử dụng qua đường miệng (ví dụ, nuốt, nhai, ngậm, đặt dưới lưỡi…)
(SEN): Tham khảo Chú giải bổ sung (SEN) của Danh mục Thuế quan hài hòa ASEAN (AHTN) 2022